KR102988319B1 - 아르테미시닌 화합물, 5-아미노레뷸린산 또는 메틸-5-아미노레뷸린산 및 화학요법제의 약제학적 조합 - Google Patents

아르테미시닌 화합물, 5-아미노레뷸린산 또는 메틸-5-아미노레뷸린산 및 화학요법제의 약제학적 조합

Info

Publication number
KR102988319B1
KR102988319B1 KR1020227032196A KR20227032196A KR102988319B1 KR 102988319 B1 KR102988319 B1 KR 102988319B1 KR 1020227032196 A KR1020227032196 A KR 1020227032196A KR 20227032196 A KR20227032196 A KR 20227032196A KR 102988319 B1 KR102988319 B1 KR 102988319B1
Authority
KR
South Korea
Prior art keywords
temozolomide
cisplatin
fluorouracil
lomustine
carboplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227032196A
Other languages
English (en)
Korean (ko)
Other versions
KR20220143097A (ko
Inventor
울리히 엘링
요제프 마틴 페닝거
Original Assignee
제이엘피 헬스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이엘피 헬스 게엠베하 filed Critical 제이엘피 헬스 게엠베하
Publication of KR20220143097A publication Critical patent/KR20220143097A/ko
Application granted granted Critical
Publication of KR102988319B1 publication Critical patent/KR102988319B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227032196A 2020-02-19 2021-02-18 아르테미시닌 화합물, 5-아미노레뷸린산 또는 메틸-5-아미노레뷸린산 및 화학요법제의 약제학적 조합 Active KR102988319B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20158341.6 2020-02-19
EP20158341.6A EP3868372A1 (en) 2020-02-19 2020-02-19 A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
PCT/EP2021/054039 WO2021165405A1 (en) 2020-02-19 2021-02-18 A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent

Publications (2)

Publication Number Publication Date
KR20220143097A KR20220143097A (ko) 2022-10-24
KR102988319B1 true KR102988319B1 (ko) 2026-07-07

Family

ID=69779738

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227032196A Active KR102988319B1 (ko) 2020-02-19 2021-02-18 아르테미시닌 화합물, 5-아미노레뷸린산 또는 메틸-5-아미노레뷸린산 및 화학요법제의 약제학적 조합

Country Status (15)

Country Link
US (1) US20230121771A1 (cg-RX-API-DMAC7.html)
EP (2) EP3868372A1 (cg-RX-API-DMAC7.html)
JP (1) JP7719787B2 (cg-RX-API-DMAC7.html)
KR (1) KR102988319B1 (cg-RX-API-DMAC7.html)
CN (1) CN114786661A (cg-RX-API-DMAC7.html)
AU (1) AU2021222339B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022014692A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165208A1 (cg-RX-API-DMAC7.html)
DK (1) DK3989961T3 (cg-RX-API-DMAC7.html)
ES (1) ES2972799T3 (cg-RX-API-DMAC7.html)
FI (1) FI3989961T3 (cg-RX-API-DMAC7.html)
IL (1) IL294856A (cg-RX-API-DMAC7.html)
PL (1) PL3989961T3 (cg-RX-API-DMAC7.html)
PT (1) PT3989961T (cg-RX-API-DMAC7.html)
WO (1) WO2021165405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184234A1 (en) * 2020-11-30 2022-06-16 Sonalasense, Inc. Metabolic targeting of low grade tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108635581A (zh) 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用
WO2019141988A1 (en) * 2018-01-17 2019-07-25 St George's Hospital Medical School Combination therapy for treatment of leukemia
US20200046679A1 (en) 2017-04-28 2020-02-13 Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd. Dihydroartemisinin-steroid conjugate and preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000051I1 (de) 1995-03-10 2007-01-04 Photocure Asa Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
JP2011225471A (ja) 2010-04-16 2011-11-10 Univ Of Tsukuba 抗癌剤の効果増強剤
US10925963B2 (en) * 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor
CN105963244A (zh) 2016-01-15 2016-09-28 赵鸣 注射用青蒿琥酯制剂及其应用
CN106527586B (zh) * 2016-11-04 2019-09-06 吉林省北方医药有限责任公司 一种移动终端设备

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200046679A1 (en) 2017-04-28 2020-02-13 Yunbaiyao Zhengwu Science and Technology (Shanghai) Co., Ltd. Dihydroartemisinin-steroid conjugate and preparation method and application thereof
WO2019141988A1 (en) * 2018-01-17 2019-07-25 St George's Hospital Medical School Combination therapy for treatment of leukemia
CN108635581A (zh) 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nat. Prod. Bioprospect., 8(4), 303-319(2018.04.09.)*

Also Published As

Publication number Publication date
PT3989961T (pt) 2024-02-26
WO2021165405A1 (en) 2021-08-26
DK3989961T3 (da) 2024-01-29
JP2023514426A (ja) 2023-04-05
AU2021222339B2 (en) 2026-05-21
IL294856A (en) 2022-09-01
JP7719787B2 (ja) 2025-08-06
BR112022014692A2 (pt) 2022-09-20
CN114786661A (zh) 2022-07-22
EP3868372A1 (en) 2021-08-25
US20230121771A1 (en) 2023-04-20
EP3989961A1 (en) 2022-05-04
FI3989961T3 (fi) 2024-02-14
AU2021222339A1 (en) 2022-07-28
KR20220143097A (ko) 2022-10-24
PL3989961T3 (pl) 2024-04-08
CA3165208A1 (en) 2021-08-26
EP3989961B1 (en) 2023-11-22
ES2972799T3 (es) 2024-06-17

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)